The 'Valsartan In Acute Myocardial Infarction' (VALIANT) trial compared valsartan with captopril in a setting of acute MI and showed it to be non-inferior to the angiotensin-converting enzyme inhibitor (ACE-I) after an acute MI with heart failure or left ventricular dysfunction [33]. This evidence concerns the gene ACE and heart failure.